CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, to assess the relevance of the miR-142 deficit to “stemness” (i.e., engrafting and disease initiating capacities) in the human disease as we observed in the mouse, we knocked-down (KD) miR-142 in LSC-enriched CD34+ cells from CP CML patients, by transducing a GFP-expressing (GFP+) anti-miR-142 lentivirus vector (Supplementary Fig. 5d, e).